(Sildenafil citrate + testosterone) is under clinical development by Freya Pharma Solutions and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Sildenafil citrate + testosterone)’s likelihood of approval (LoA) and phase transition for Female Hypoactive Sexual Desire Disorder took place on 21 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Sildenafil citrate + testosterone) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Sildenafil citrate + testosterone) overview

Sildenafil citrate in a fixed dose combination with testosterone (Lybrido) is under development for the treatment of female sexual dysfunction and hypoactive sexual desire disorder. The drug candidate is administered orally and sublingually. The drug candidate is a fixed-combination with an inner core of sildenafil with a polymeric time delay coating and an outer polymeric coating containing testosterone. Sildenafil citrate targets enzyme phosphodiesterase 5 (PDE5) and testosterone targets androgen receptor.

Freya Pharma Solutions overview

Freya Pharma Solutions (Freya) is a biotech business focused on the discovery of effective pharmacological therapeutics for female sexual interest/arousal problem in late-stage clinical trials (FSIAD). Freya is headquartered in Amsterdam, North Holland, The Netherlands.

Quick View (Sildenafil citrate + testosterone) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Sildenafil citrate + testosterone)
Administration Pathway
  • Oral
  • Sublingual
Therapeutic Areas
  • Women’s Health
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.